CA3175526A1 - Pirfenidone for coronavirus treatment - Google Patents
Pirfenidone for coronavirus treatmentInfo
- Publication number
- CA3175526A1 CA3175526A1 CA3175526A CA3175526A CA3175526A1 CA 3175526 A1 CA3175526 A1 CA 3175526A1 CA 3175526 A CA3175526 A CA 3175526A CA 3175526 A CA3175526 A CA 3175526A CA 3175526 A1 CA3175526 A1 CA 3175526A1
- Authority
- CA
- Canada
- Prior art keywords
- approximately
- pirfenidone
- release
- subject
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063010009P | 2020-04-14 | 2020-04-14 | |
| US63/010,009 | 2020-04-14 | ||
| PCT/US2021/027335 WO2021211745A1 (en) | 2020-04-14 | 2021-04-14 | Pirfenidone for coronavirus treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3175526A1 true CA3175526A1 (en) | 2021-10-21 |
Family
ID=78084909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3175526A Pending CA3175526A1 (en) | 2020-04-14 | 2021-04-14 | Pirfenidone for coronavirus treatment |
Country Status (14)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| MX368750B (es) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| CN114796122B (zh) * | 2022-03-30 | 2023-03-24 | 山东大学 | 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用 |
| JP7845721B2 (ja) * | 2022-04-29 | 2026-04-14 | オーバーシーズ ファーマシューティカルズ リミテッド | ピルフェニドンの経口用持続放出性固形製剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU709178B2 (en) * | 1995-09-19 | 1999-08-26 | Intermune, Inc. | Inhibition of tumor necrosis factor alpha |
| US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| US20030103941A1 (en) * | 2001-10-09 | 2003-06-05 | Crombleholme Timothy M. | Materials and methods for preventing or reducing scar formation |
| WO2005013917A2 (en) * | 2003-02-28 | 2005-02-17 | Intermune, Inc. | Combination therapy for treating alphavirus infection and liver fibrosis |
| WO2005000227A2 (en) * | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| WO2005040758A2 (en) * | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| AP2007004244A0 (en) * | 2005-05-10 | 2007-12-31 | Intermune Inc | Method of modulating stress-activated protein kinase system |
| NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| CN101088557A (zh) * | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| WO2010132864A1 (en) * | 2009-05-15 | 2010-11-18 | Intermune, Inc. | Methods of treating hiv patients with anti-fibrotics |
| CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
| HUE058753T2 (hu) * | 2011-01-31 | 2022-09-28 | Avalyn Pharma Inc | Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| WO2013181691A1 (en) * | 2012-06-04 | 2013-12-12 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor |
| JP7066321B2 (ja) * | 2014-01-10 | 2022-05-13 | アヴァリン ファーマ インク. | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 |
-
2021
- 2021-04-14 KR KR1020227039706A patent/KR20230038644A/ko active Pending
- 2021-04-14 WO PCT/US2021/027335 patent/WO2021211745A1/en not_active Ceased
- 2021-04-14 AU AU2021254765A patent/AU2021254765A1/en not_active Abandoned
- 2021-04-14 US US17/918,791 patent/US20230117397A1/en not_active Abandoned
- 2021-04-14 MX MX2022012986A patent/MX2022012986A/es unknown
- 2021-04-14 BR BR112022020821A patent/BR112022020821A2/pt not_active Application Discontinuation
- 2021-04-14 EP EP21788910.4A patent/EP4135671A4/en not_active Withdrawn
- 2021-04-14 CA CA3175526A patent/CA3175526A1/en active Pending
- 2021-04-14 CN CN202180042472.1A patent/CN115916162A/zh active Pending
- 2021-04-14 IL IL297296A patent/IL297296A/en unknown
- 2021-04-14 JP JP2022562668A patent/JP2023521887A/ja active Pending
-
2022
- 2022-10-14 CL CL2022002843A patent/CL2022002843A1/es unknown
- 2022-11-11 CO CONC2022/0016155A patent/CO2022016155A2/es unknown
- 2022-11-14 EC ECSENADI202287664A patent/ECSP22087664A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022002843A1 (es) | 2023-09-01 |
| CN115916162A (zh) | 2023-04-04 |
| MX2022012986A (es) | 2023-03-21 |
| EP4135671A1 (en) | 2023-02-22 |
| ECSP22087664A (es) | 2022-12-30 |
| BR112022020821A2 (pt) | 2022-12-20 |
| IL297296A (en) | 2022-12-01 |
| KR20230038644A (ko) | 2023-03-21 |
| EP4135671A4 (en) | 2024-08-14 |
| US20230117397A1 (en) | 2023-04-20 |
| WO2021211745A1 (en) | 2021-10-21 |
| AU2021254765A1 (en) | 2022-12-08 |
| CO2022016155A2 (es) | 2022-12-20 |
| JP2023521887A (ja) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230117397A1 (en) | Pirfenidone for coronavirus treatment | |
| CN114786659B (zh) | 用于治疗汉坦病毒感染的mek抑制剂 | |
| US20200323843A1 (en) | Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus | |
| JP2007291067A (ja) | 医薬組成物 | |
| JP2023521887A5 (cg-RX-API-DMAC7.html) | ||
| JP7701757B2 (ja) | タウロデオキシコール酸またはその薬学的に許容される塩を有効成分として含む新型コロナウイルス感染症(covid-19)の治療用組成物 | |
| US12064509B2 (en) | Enema for rectal application | |
| CA3190278A1 (en) | Antiviral use of liraglutide and gefitinib | |
| JP2010083871A (ja) | 抗アデノウイルス剤を含有する医薬組成物 | |
| JP5134802B2 (ja) | 塩酸ブロムヘキシン含有量低下の防止方法 | |
| CN101966190A (zh) | 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂 | |
| JP2023523410A (ja) | 上気道感染症を治療するための組成物および方法 | |
| JP2004331660A (ja) | 医薬組成物 | |
| ZA200500064B (en) | Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib. | |
| CN119139378A (zh) | 神香草挥发油及包含其的组合物在制备治疗特发性肺纤维化药物中的应用 | |
| Habawel et al. | Comparative Efficacy of Different Fixed Drug Combinations on Clinical Signs of Respiratory Disease in Starter Pigs. | |
| HK40094222A (en) | Amiselimod for preventing, treating, or ameliorating ulcerative colitis | |
| CN105362226A (zh) | 氨溴索沙丁胺醇气雾剂的制备方法 | |
| KR20230098780A (ko) | 코로나바이러스에 대한 티아졸리드의 용도 | |
| CN105456240A (zh) | 氨溴索沙丁胺醇气雾剂 | |
| KR20150063040A (ko) | 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제 | |
| CN102552257A (zh) | 一种含有盐酸雷尼替丁和曲昔派特的复方制剂及其用途 | |
| HK1199815B (en) | Levocetirizine and montelukast for the treatment of influenza and common cold | |
| CN105434412A (zh) | 氨溴索沙丁胺醇控释胶囊 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250929 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260203 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260526 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260709 |